Changeflow GovPing Healthcare & Life Sciences EP4157880A2 - Osteoarthritis Treatment Methods ...
Routine Notice Added Final

EP4157880A2 - Osteoarthritis Treatment Methods and Compositions

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

The EPO published European patent application EP4157880A2, filed by the New York Society for the Relief of the Ruptured and Crippled, Maintaining the Hospital for Special Surgery, covering methods and compositions for treating, preventing the onset, and/or slowing the progression of osteoarthritis. The application names Miguel Otero Adran and Purva Singh as inventors and lists IPC classifications C07K 16/28, C07K 16/30, A61K 39/395, and A61K 47/68, indicating pharmaceutical compositions including antibodies and antibody-drug conjugates. The publication designates all European patent contracting states, establishing a priority date for the disclosed therapeutic approach.

“METHODS AND COMPOSITIONS FOR TREATING, PREVENTING THE ONSET AND/OR SLOWING PROGRESSION OF OSTEOARTHRITIS”

EPO , verbatim from source
Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Peptides (C07K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 58 changes logged to date.

What changed

The EPO Patent Bulletin published application EP4157880A2 for methods and compositions treating osteoarthritis, filed by the New York Society for the Relief of the Ruptured and Crippled, Maintaining the Hospital for Special Surgery. The A2 publication kind indicates an international search report has been issued. The application covers therapeutic compositions including antibodies and antibody-drug conjugates per the IPC classifications C07K 16/28, C07K 16/30, A61K 39/395, and A61K 47/68. Inventors are Miguel Otero Adran and Purva Singh.

Pharmaceutical companies and medical device manufacturers engaged in osteoarthritis therapeutic development should monitor this publication for competitive intelligence purposes. The A2 publication establishes a priority date for the disclosed compositions; it does not constitute a granted patent and does not itself confer enforceable patent rights. Parties developing similar biologics or antibody-based osteoarthritis therapies should evaluate freedom-to-operate implications once the application proceeds toward grant.

Archived snapshot

Apr 25, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

METHODS AND COMPOSITIONS FOR TREATING, PREVENTING THE ONSET AND/OR SLOWING PROGRESSION OF OSTEOARTHRITIS

Publication EP4157880A2 Kind: A2 Apr 15, 2026

Applicants

New York Society for the Relief of the
Ruptured and Crippled, Maintaining the
Hospital for Special Surgery

Inventors

OTERO ADRAN, Miguel, SINGH, Purva

IPC Classifications

C07K 16/28 20060101AFI20240610BHEP C07K 16/30 20060101ALI20240610BHEP A61K 39/395 20060101ALI20240610BHEP A61K 47/68 20170101ALI20240610BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application IP strategy Therapeutic development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Medical Devices Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!